Navigation Links
Flurizan's Effect in Delaying Progression From Mild Cognitive Impairment to Alzheimer's Disease is Superior to That of Aricept
Date:2/5/2008

Following its Launch in 2010, Myriad Genetics' Flurizan Will Earn a 23% Patient Share in the United States, According to a New Report from Decision

Resources

WALTHAM, Mass., Feb. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on delaying the progression from mild cognitive impairment to Alzheimer's disease is the attribute that most influences neurologists' prescribing decisions in the treatment of mild cognitive impairment. Clinical trial data and expert opinion shows that Myriad Genetics' Flurizan has advantages in this attribute over Eisai/Pfizer's Aricept/Bracco's Memac, the current sales leader and gold standard therapy for mild cognitive impairment.

The new report entitled Mild Cognitive Impairment: An Off-Label Market with Significant Unmet Need and High Prevalence Carries Substantial Opportunity finds that, following its launch in 2010, Flurizan will replace Aricept as the gold standard for mild cognitive impairment. Surveyed U.S. neurologists indicate that they would prescribe Flurizan to 20% of their patients with mild cognitive impairment and the report forecasts that Flurizan will earn a 23% patient share in the U.S. market in 2016.

"Clinical trial data suggests that Flurizan has disease-modifying properties, an asset that interviewed experts expect will make the drug more effective at delaying the onset of Alzheimer's disease than currently available drugs," said Bethany Kiernan, Ph.D., analyst at Decision Resources. "Flurizan's safety and tolerability profile is also better than other emerging competitors, and this, along with its efficacy, will make it the gold standard in the treatment of mild cognitive impairment in 2016."

About the Report

Mild Cognitive Impairment: An Off-Label Market with Significant Unmet Need and High Prevalence Carries Substantial Opportunity is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
2. DNA sensors found to be an effective artificial nose
3. Free White Paper Available for Clinical Laboratory Managers: Effectively Isolating Anaerobic Bacteria
4. Job-related stress: NIST demonstrates fatigue effects in silicon
5. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
6. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
7. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
8. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
9. New nanoparticle vaccine is more effective but less expensive
10. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
11. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, ... in analytical testing are being attributed to new regulatory requirements for all new ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... ... 11, 2017 , ... Proscia Inc ., a data ... titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, ... and how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
Breaking Biology News(10 mins):